What happened with NRIX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Nurix Therapeutics is developing medicines for cancer and other difficult-to-treat diseases. Its targeted protein degradation approach aims to make cells remove disease-causing proteins. It uses its DEL-AI discovery platform to find drug candidates and is advancing its own candidates, including bexobrutideg, through early clinical trials. It has no approved products and has not earned revenue from drug sales.
Revenue comes from research collaborations and licenses with Gilead, Sanofi and Pfizer. Nurix discovers drug candidates for these partners, which generally take responsibility for further development and commercialization after licensing them. The partners pay upfront fees, research funding and payments tied to licensing or development milestones. Nurix may also earn royalties if partnered drugs reach the market.
The business depends on these partners continuing to support their programs and on research reaching payment-triggering milestones. Selling its own medicines requires successful clinical trials and regulatory approval. Nurix also funds operations through equity financing and needs substantial additional funding to continue development.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Nurix’s prospects hinge on clinical success for its protein-degrader pipeline and partner funding; C4 Therapeutics is another protein-degradation rival to watch beyond this list.
BeOne Medicines directly challenges Nurix’s NX-5948 with its BGB-16673 BTK degrader, while selling BRUKINSA in the same B-cell malignancy market. Watch BGB-16673’s clinical progress for the closest pipeline comparison and BRUKINSA sales for BeOne’s commercial position in that market.
Kymera Therapeutics and Nurix both develop small-molecule protein degraders and license programs to drug companies, so clinical validation and partner demand matter to both, although Kymera focuses mainly on immunology. Watch whether Sanofi advances Kymera’s KT-485/SAR447971 into clinical testing as expected in 2026.
Arvinas’s clinical progress offers Nurix holders evidence about protein degradation as a treatment approach: Arvinas develops PROTAC degraders, while Nurix uses its own discovery platform. Its vepdegestrant partnership with Pfizer, which shares development costs and offers potential milestone payments, also makes the planned selection of a third party for commercialization worth watching.
Monte Rosa Therapeutics offers a comparison for Nurix’s partner-funded discovery business: it discovers molecular glue degraders and licenses them to drug companies. Novartis paid $150 million upfront for programs including MRT-6160 and bears subsequent clinical-study costs, except Monte Rosa’s share of Phase 3 costs, making that program’s progress a concrete test of this funding model.
Nurix depends on Pfizer to pay for protein degraders, attach them to antibodies, and advance the partnered medicines toward sale, subject to Nurix’s profit-sharing options. Watch Pfizer’s funding and development decisions for these programs: Nurix recognized $25.7 million in Pfizer collaboration revenue in the year ended November 30, 2025.
Sanofi pays Nurix for discovery research and licensed targets, then controls clinical development and commercialization, subject to Nurix’s options to participate in U.S. products. Its exercise of rights for two targets in 2025 generated $30 million of Nurix license revenue in the year ended November 30, 2025; further progress on those targets matters for future payments.
Gilead Sciences funds Nurix’s research on specific targets and licenses resulting drug candidates to develop and sell, giving Nurix potential milestones, sales royalties and U.S. profit-sharing. Watch new license decisions and research extensions: Nurix’s Gilead collaboration revenue fell from $14 million to $7.1 million between the years ended November 30, 2024 and 2025.
Eli Lilly’s pirtobrutinib competes with Nurix’s BTK degraders as a next-generation treatment targeting the BTK pathway in chronic lymphocytic leukemia (CLL). For Nurix holders, pirtobrutinib’s role in frontline CLL combinations is the relevant competitive development to watch, rather than Lilly’s broader medicine sales.
AstraZeneca already sells acalabrutinib for CLL, giving Nurix’s BTK degraders an established BTK-directed treatment to compete against. Watch its approved combination with venetoclax as a concrete benchmark for the CLL treatment market Nurix seeks to enter.
Gilead Sciences Inc earningsGILD
Gilead’s report can show whether it is continuing target research and licensing with Nurix, which can bring Nurix collaboration payments and later milestones.
Look for a new license or research extension from Gilead, and read it alongside Nurix’s Gilead collaboration revenue. New licenses or continued research would show Gilead is advancing the partnership and could bring Nurix fees or milestones. No such progress alongside lower revenue would leave Nurix more reliant on other partners and its existing cash.
Eli Lilly & Co. earningsLLY
Lilly’s report may show whether its BTK inhibitor pirtobrutinib is moving into first-line CLL combinations, a key competitive signal for Nurix’s BTK degraders.
Look for Lilly to report progress placing pirtobrutinib in first-line combinations for CLL. Clear progress would mean Nurix’s BTK degraders could face competition earlier in treatment. Without such progress, the identified competitive signal remains in other treatment settings; that alone does not establish whether Nurix’s candidates will succeed.
BeOne Medicines Ltd. earningsONC
BeOne’s report can show progress for its BTK degrader BGB-16673 and BRUKINSA sales in related blood cancers, revealing two parts of the competitive landscape for Nurix.
Separate BGB-16673’s clinical progress from BRUKINSA sales. Progress for the degrader would make it a direct pipeline rival to Nurix’s NX-5948. Strong BRUKINSA sales would show BeOne has an established commercial position in related B-cell cancers, where Nurix would eventually face existing treatments. Little progress on either front would mean weaker signals from this competitor, not proof that Nurix’s candidates work.
